Genmab A (GMAB) Interest & Investment Income (2019 - 2026)
Genmab A's (GMAB) quarterly Interest & Investment Income came in at $44.0 million in Q1 2026, down 56.44% YoY from $101.0 million in Q1 2025, and down 85.9% on a QoQ basis from $312.0 million in Q3 2025.
Genmab A (GMAB) Interest & Investment Income (2019 - 2026) Analysis & Trends
Genmab A (GMAB) has 7 years of Interest & Investment Income data on file, last reported at $44.0 million in Q1 2026.
- Quarterly Interest & Investment Income fell 56.44% year-over-year to $44.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $710.0 million (down 19.41% YoY) and the FY2025 annual result came in at $408.0 million, down 36.74% from the prior year.
- Interest & Investment Income fell to $44.0 million in Q1 2026, from $312.0 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $328.0 million in Q3 2024 to a low of $44.0 million in Q1 2026.
- A 4-year average of $203.4 million and a median of $210.5 million in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2025 — Interest & Investment Income dropped 4.88% — and 2026, when it slumped 56.44%.
- Tracing GMAB's Interest & Investment Income over 4 years: stood at $137.0 million in 2023, then surged by 139.42% to $328.0 million in 2024, then declined by 4.88% to $312.0 million in 2025, then plunged by 85.9% to $44.0 million in 2026.
- The last three Interest & Investment Income figures came in at $44.0 million (Q1 2026), $312.0 million (Q3 2025), and $253.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.68 Bn | 77.69 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.75 Bn | 58.57 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 61.17 Bn | 56.03 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 27.84 Bn | 9.44 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Royalty Pharma | 27.53 Bn | 26.69 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.38 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Genmab A | 2.22 Bn | 719.53 Mn | 1.07 Bn | 59.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.00 Mn |
| Mar 31, 2026 | 44.00 Mn |
| Sep 30, 2025 | 312.00 Mn |
| Jun 30, 2025 | 253.00 Mn |
| Mar 31, 2025 | 101.00 Mn |
| Sep 30, 2024 | 328.00 Mn |
| Jun 30, 2024 | 284.00 Mn |
| Mar 31, 2024 | 168.00 Mn |
| Dec 31, 2023 | 137.00 Mn |
| Mar 31, 2021 | 62.00 Mn |
| Sep 30, 2020 | 533.00 |
| Mar 31, 2020 | 41.00 Mn |
| Dec 31, 2019 | 356.00 |